Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Clinical Diabetes and Healthcare|December 17, 2025
The effect of HbA1C variability on the development and progression of diabetic nephropathyAlper Coskun, Aslihan Calim, Emre Sedar Saygili, et al.
Cancer Management and Research|June 11, 2026
Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with NivolumabAlper Coskun, Eyyup Cavdar, Seda Sali, et al.
Technology in Cancer Research & Treatment|May 5, 2026
Prognostic Impact of Blood Transfusions During Nivolumab Therapy in Metastatic Non-Small Cell Lung CancerAlper Coskun, Eyyup Cavdar, Ece Tolgay, et al.
Current Oncology (Toronto, Ont.)|July 25, 2025
Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary Bladder: A Propensity Score-Matched AnalysisAlper Coskun, Ahmet Bilgehan Sahin, Selva Kabul, et al.
Oncology Letters|May 28, 2026
Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancerAlper Coskun, Ahmet Bilgehan Sahin, Selva Kabul, et al.
The Oncologist|June 30, 2025
Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breastSeda Sali, Mursel Sali, Burcu Caner, et al.
Frontiers in Oncology|January 8, 2025
Left ventricular global longitudinal strain in patients treated with immune checkpoint inhibitorsEce Celebi Coskun, Alper Coskun, Ahmet Bilgehan Sahin, et al.
Clinical Breast Cancer|May 16, 2025
Biologically Informed Decision-Making for PMRT in pT3N0M0 Luminal Breast Cancers (Protocol MF22-02): International Multicenter Real-World DataAtilla Soran, Melis Bahadir Gultekin, Bhanu Prasad Venkatesulu, et al.
Cancers|January 11, 2025
Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life StudySalih Tünbekici, Haydar Cagatay Yuksel, Caner Acar, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|April 17, 2025
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)Nargiz Majidova, Sendag Yaslıkaya, Maral Martin Mıldanoglu, et al.
Pageof 3